Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est
Benzinga Newsdesk 3 weeks ago
NewsGuidance
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2026 sales outlook from $860.000 million-$890.000 million to $875.000 million-$900.000 million vs $877.738 million estimate.
Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2026 sales outlook from $860.000 million-$890.000 million to $875.000 million-$900.000 million vs $877.738 million estimate.
More on SUPN
Analyst ratings Benzinga
Wells Fargo Initiates Coverage On Supernus with Overweight Rating, Announces Price Target of $54Wells Fargo analyst Tianqi Hang initiates coverage on Supernus (NASDAQ:SUPN) with a Overweight rating and announces Price Target of $54.
